Aytu Biopharma (AYTU) Income from Continuing Operations (2010 - 2026)
Aytu Biopharma (AYTU) posted quarterly Income from Continuing Operations of 5618000.0 for Q1 2026, down 243.39% year-over-year from 3918000.0 in Q1 2025, and up 46.92% quarter-over-quarter from 10584000.0 in Q4 2025.
Aytu Biopharma (AYTU) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Income from Continuing Operations for 17 consecutive years, with 5618000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 243.39% year-over-year to 5618000.0; the TTM figure through Mar 2026 stood at 33706000.0 (down 1420.25% YoY), while the FY2025 annual figure was 13771000.0, down 12.29% from the prior year.
- Income from Continuing Operations climbed to 5618000.0 in Q1 2026 per AYTU's latest filing, from 10584000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6960000.0 in Q2 2022 and bottomed at 53291000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 6099823.53 across 5 years, with a median of 2457000.0 in 2023.
- On a YoY basis, Income from Continuing Operations climbed as much as 271.24% in 2025 and fell as far as 1691.58% in 2025.
- Aytu Biopharma's Income from Continuing Operations stood at 6693000.0 in 2022, then soared by 108.95% to 599000.0 in 2023, then gained by 11.02% to 665000.0 in 2024, then slumped by 1691.58% to 10584000.0 in 2025, then jumped by 46.92% to 5618000.0 in 2026.
- Business Quant data shows AYTU's Income from Continuing Operations at 5618000.0 in Q1 2026, 10584000.0 in Q4 2025, and 1965000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Aytu Biopharma | 24.86 Mn | -1.86 Mn | 7.60 Mn | -5.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.62 Mn |
| Dec 31, 2025 | -10.58 Mn |
| Sep 30, 2025 | 1.97 Mn |
| Jun 30, 2025 | -19.47 Mn |
| Mar 31, 2025 | 3.92 Mn |
| Dec 31, 2024 | 665,000.00 |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | -3.12 Mn |
| Mar 31, 2024 | -2.29 Mn |
| Dec 31, 2023 | 599,000.00 |
| Sep 30, 2023 | -7.47 Mn |
| Jun 30, 2023 | -2.46 Mn |
| Mar 31, 2023 | -7.20 Mn |
| Dec 31, 2022 | -6.69 Mn |
| Sep 30, 2022 | -701,000.00 |
| Jun 30, 2022 | 6.96 Mn |
| Mar 31, 2022 | -53.29 Mn |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -27.85 Mn |
| Jun 30, 2021 | -18.74 Mn |